Keywords: زمان به پیشرفت; Hepatocellular carcinoma; Resection plus radiofrequency ablation; Transarterial embolization; Survival; Time to progression;
مقالات ISI زمان به پیشرفت (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: زمان به پیشرفت; metastatic breast cancer; MBC; lobaplatin and gemcitabine; GL; lobaplatin and vinorelbine; NL; cisplatin and gemcitabine; GP; cisplatin and vinorelbine; NP; progression-free survival; PFS; overall survival; OS; response rate; RR; platinum-based compounds;
Keywords: زمان به پیشرفت; AE; adverse event; AUC; area under the curve; CI; confidence interval; Cmax; maximum concentration; HCC; hepatocellular carcinoma; HR; hazard ratio; OS; overall survival; PK; pharmacokinetic; PVA; polyvinyl alcohol; TTP; time to progression; W/O; water-in
Keywords: زمان به پیشرفت; 5FU; 5-fluorouracil; 95%CI; 95% confidence interval; AA; amino acid; AFP; alpha fetoprotein; AML; actue myeloid leukemia; Ang2; angiopoietin 2; ATP; adenosine triphosphate; BCLC; Barcelona-Clinic Liver Cancer classification; BSC; best supportive care; CAP
Keywords: زمان به پیشرفت; AE; adverse event; ADR; adverse drug reaction; ANC; absolute neutrophil count; CI; confidence interval; CR; complete remission; CTCAE; common terminology criteria for adverse events; DEX; dexamethasone; ECOG; eastern cooperative oncology group; eCRF; elec
Keywords: زمان به پیشرفت; DLBCL; diffuse large B-cell lymphoma; R-CHOP; rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; NHL; non-Hodgkin lymphoma; GEP; gene expression profiling; COO; cell-of-origin; GCB; germinal center B-cell; ABC; activated B-cell; PMBL;
Keywords: زمان به پیشرفت; Androgen deprivation therapy; Advanced prostate cancer; Time to progression; Predictive factor;
Keywords: زمان به پیشرفت; AH/AL; heavy/light chain amyloidosis; AL; immunoglobulin light chain amyloidosis; ALL; localized immunoglobulin light chain amyloidosis; BSC; best supportive care; DMSO; dimethyl sulfoxide; IFE; immunofixation; MALT; mucosa-associated lymphoid tissue; MGU
Keywords: زمان به پیشرفت; FDA; Food and Drug Administration; MEK; mitogen-activated protein kinase kinase; MRI; magnetic resonance imaging; NF1; neurofibromatosis type 1; OPPN; orbital-periorbital plexiform neurofibroma; PN; plexiform neurofibroma; TTP; time to progression;
Keywords: زمان به پیشرفت; Breast cancer; Subsequent chemotherapy; Progression-free survival; Time to progression; Objective response rate; Cancer du sein; Chimiothérapie; Survie globale; Survie sans progression; Taux de réponse;
Keywords: زمان به پیشرفت; CI; confidence interval; CR; complete response; HBV; hepatitis B virus; HCC; hepatocellular carcinoma; IQR; interquartile range; LEM; Lipiodol and ethanol mixture; OS; overall survival; PFS; progression-free survival; TEA; transarterial ethanol ablation;
Keywords: زمان به پیشرفت; AST; aspartate aminotransferase; BSA; body surface area; CI; confidence interval; CP; Child-Pugh; HCC; hepatocellular carcinoma; HR; hazard ratio; OS; overall survival; PVT; portal vein thrombosis; TTP; time to progression; TTT; time to toxicity; 90Y; ytt
Keywords: زمان به پیشرفت; AA; accelerated approval; ALL; acute lymphoblastic leukemia; CCyR; complete cytogenetic response; CLL; chronic lymphocytic lymphoma; CML; chronic myeloid leukemia; CRC; colorectal carcinoma; CR; complete response; CRi; complete response with incomplete bl
Keywords: زمان به پیشرفت; Breast cancer; Clinical trial; End-point; Progression free survival; Time to progression; Time to treatment failure
Keywords: زمان به پیشرفت; SBRT; stereotactic body radiation therapy; HCC; hepatocellular carcinoma; RECIST; response evaluation criteria in solid tumors; CTCAE; common terminology criteria for adverse events; LC; local control; OS; overall survival; PFS; progression-free survival;
Keywords: زمان به پیشرفت; AFP; alpha fetoprotein; HBsAg; hepatitis B surface antigen; HCC; hepatocellular carcinoma; TTP; time to progression;
Keywords: زمان به پیشرفت; HCC; hepatocellular carcinoma; TTP; time to progression; NTUH; National Taiwan University Hospital; OS; overall survival; BCLC; Barcelona Clinic Liver Cancer; CLIP; Cancer of the Liver Italian Program; ECOG PS; Eastern Cooperative Oncology Group performan
Keywords: زمان به پیشرفت; CI; confidence interval; EASL; European Association for the Study of the Liver; HCC; hepatocellular carcinoma; PVT; portal vein thrombosis; TIPS; transjugular intrahepatic portosystemic shunt; TTP; time to progression; 90Y; yttrium-90;
Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma
Keywords: زمان به پیشرفت; CI; confidence interval; CR; complete response; HCC; hepatocellular carcinoma; HR; hazard ratio; IQR; interquartile range; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PR; partial response; PSM; propensity score matching; RS; radiation
Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials
Keywords: زمان به پیشرفت; Advanced breast cancer; Clinical trial; Overall survival; Progression-free survival; Time to progression;
CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin
Keywords: زمان به پیشرفت; CI; ConfidenceInterval; CT; ComputedTomography; CTTA; CT-TexturalAnalysis; DCR; Disease Control Rate; DNA; DeoxyribonucleicAcid; FDG-PET; Fludeoxyglucose-Positron Emission Tomography; Fig.; Figure; GIST; Gastrointestinal Stromal Tumor; NGLD; MNeighboring
Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic
Keywords: زمان به پیشرفت; ALL; Acute lymphoblastic leukemia; AML; Acute myeloid leukemia; AUC; Area under the curve; AZA; 5-azacytidine; 5-aza-CdR; 2â²-deoxy-5-azacytidine; 5-aza-CR; 5-azacytidine; AZN; Azanucleosides; BED; Biologically effective dose; BSC; Best supportive care;
HIP1 expression predicts outcome in breast cancer patients treated with neoadjuvant chemotherapy
Keywords: زمان به پیشرفت; HIP1; huntingtin-interacting protein 1; p; patients; IHC; immunohistochemistry (IHC); TTP; time to progression; OS; overall survival; TNBC; triple negative breast cancer; DLBCL; diffuse large B-cell lymphoma; R-CHOP; rituximab, cyclophosphamide, doxorubic
Cone Beam CT-Guided Chemoembolization of Probable Hepatocellular Carcinomas Smaller than 1 cm in Patients at High Risk of Hepatocellular Carcinoma
Keywords: زمان به پیشرفت; CI; confidence interval; CTP; Child-Turcotte-Pugh; DSA; digital subtraction angiography; HCC; hepatocellular carcinoma; HR; hazard ratio; MELD; Model for End-stage Liver Disease; TTLP; time to local progression; TTP; time to progression;
Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy
Keywords: زمان به پیشرفت; BCLC; Barcelona Clinic Liver Cancer; CLM; colorectal carcinoma liver metastases; CRC; colorectal carcinoma; DEBIRI; drug-eluting beads loaded with irinotecan; DEE; drug-eluting embolic; ECOG; Eastern Cooperative Oncology Group; GM-CSF; granulocyte-macroph
Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival
Keywords: زمان به پیشرفت; BCLC; Barcelona Clinic for Liver Cancer; CI; confidence interval; EASL; European Association for the Study of the Liver; ECOG; Eastern Cooperative Oncology Group; HCC; hepatocellular carcinoma; OS; overall survival; PVT; portal vein thrombosis; TTP; time
Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria
Keywords: زمان به پیشرفت; CR; complete response, EASL = European Association for the Study of the Liver; HCC; hepatocellular carcinoma; MAA; macroaggregated albumin; mRECIST; modified Response Evaluation Criteria In Solid Tumors; PET; positron emission tomography; PFS; progression
Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
Keywords: زمان به پیشرفت; Randomized Trial; Chemoembolization; Radioembolization; Liver Cancer; BCLC; Barcelona Clinic Liver Cancer; CI; confidence interval; CT; computed tomography; cTACE; conventional transarterial chemoembolization; EASL; European Association for the Study of t
Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma
Keywords: زمان به پیشرفت; BM; bone marrow; B-SLL; B-cell small lymphocytic lymphoma; CR; complete remission; DLBCL; diffuse large B-cell lymphoma; DTH; delayed-type hypersensitivity; FC; flow cytometry; FL; follicular lymphoma; HSP; heat shock protein; HSPPC; heat shock protein-pe
Original StudyAn Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer
Keywords: زمان به پیشرفت; Eribulin mesylate; Overall survival; Phase II clinical trial; Progression-free survival; Time to progression;
Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival
Keywords: زمان به پیشرفت; AFP; α-fetoprotein; BCLC; Barcelona Clinic Liver Cancer; CI; confidence interval; ECOG; Eastern Cooperative Oncology Group; HBV; hepatitis B virus; HBV-HCC; hepatocellular carcinoma resulting from hepatitis B virus etiology; HCC; hepatocellular carcinoma
Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
Keywords: زمان به پیشرفت; Prostate cancer; Natural history; Survival; Time to progression; Control arm cohort; Hormone-naïve; Metastatic; Prognostic factors; Prospective data;
Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma
Keywords: زمان به پیشرفت; HCC; hepatocellular carcinoma; ATO; arsenic trioxide; APL; acute promyelocytic leukemia; PML; promyelocytic leukemia protein; RARα; retinoic acid receptor α; ALDH3A1; aldehyde dehydrogenase 3 family member A1; qRT-PCR; quantitative real-time reverse tra
Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis
Keywords: زمان به پیشرفت; BCLC; Barcelona Clinic Liver Cancer; CI; confidence interval; HCC; hepatocellular carcinoma; HR; hazard ratio; IPTW; inverse probability of treatment weighted; IQR; interquartile range; OS; overall survival; PV; portal vein; PVTT; portal vein tumor thromb
Research ArticleEarly dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Keywords: زمان به پیشرفت; OS; Overall survival; HCC; Hepatocellular carcinoma; AE; adverse events; PS; Performance status; BCLC; Barcelona Clinic Liver Cancer classification; TTP; Time to progression; AASLD; American Association for the Study of Liver Disease; AE60; AE with in the
Genetics of rare mesenchymal tumors: Implications for targeted treatment in DFSP, ASPS, CCS, GCTB and PEComa
Keywords: زمان به پیشرفت; DFSP; dermatofibrosarcoma protuberans; ASPS; alveolar soft part sarcoma; CCS; clear cell sarcoma; GCTB; giant cell tumor of bone; PEComas; perivascular epithelioid cell neoplasm; PDGFRB; platelet-derived growth factor receptor, beta; MET; met proto-oncoge
Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens
Keywords: زمان به پیشرفت; Ecteinascidin-743; Objective response rate; Overall survival; Progression-free survival; Safety; Time to progression;
RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner
Keywords: زمان به پیشرفت; GTPase; Non-cell autonomous; Microenvironment; Tumor-stroma; MMP; Chemotherapy; Radiotheraphy; Drug target; ADC; Adenocarcinoma; SQ; squamous cell carcinoma; TP; time to progression; i.c.; intracardiac; i.t.; intratibial; HMS; highly-metastatic subpopulat
Yttrium-90 Radioembolization Stops Progression of Targeted Breast Cancer Liver Metastases after Failed Chemotherapy
Keywords: زمان به پیشرفت; BCLM; breast cancer liver metastasis; CA-27.29; cancer antigen 27.29; CI; confidence interval; HR; hazard ratio; mBC; metastatic breast cancer; OS; overall survival; PD; progressive disease; PET; positron emission tomography; PR; partial response; RECIST;
Research ArticleGemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study
Keywords: زمان به پیشرفت; HCC; hepatocellular carcinoma; OS; overall survival; AFP; α-fetoprotein; TACE; transarterial chemoembolization; TTP; time to progression; PFS; progression-free survival; PS; performance status; CLIP; Cancer of the Liver Italian Program; ORR; overall resp
Research ArticleA clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Keywords: زمان به پیشرفت; HCV; hepatitis C virus; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; RECIST; Response Evaluation Criteria in Solid Tumor; TTP; time to progression; Liver cancer; Immunotherapy; CTLA-4; Treg;
Safety and Efficacy of Maintenance Therapy With a Nonspecific Cytochrome P17 Inhibitor (CYP17i) After Response/Stabilization to Docetaxel in Metastatic Castration-Resistant Prostate Cancer
Keywords: زمان به پیشرفت; Cytochrome P17 inhibitor (CYP17i); Docetaxel; Maintenance therapy; mCRPC; Time to progression
Cancer Concepts and Principles: Primer for the Interventional Oncologist-Part I
Keywords: زمان به پیشرفت; CR; complete response; DCR; disease control rate; EASL; European Association for the Study of the Liver; FDA; Food and Drug Administration; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria in Solid Tumors; NCCN; National Compr
Single-center Comparison of Three Chemoembolization Regimens for Hepatocellular Carcinoma
Keywords: زمان به پیشرفت; CDM; cisplatin/doxorubicin/mitomycin-c/ethiodized oil; CR; complete response; DE; doxorubicin/ethiodized oil; DEB; drug-eluting bead; HCC; hepatocellular carcinoma; mRECIST; modified Response Evaluation Criteria in Solid Tumors; PACS; picture archiving an
Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Are Superior to European Association for Study of the Liver (EASL) Criteria at 1 Month Follow-up for Predicting Long-term Survival in Patients Treated with Transarterial Chemoembolization befo
Keywords: زمان به پیشرفت; EASL; European Association for Study of the Liver; HCC; hepatocellular carcinoma; LT; liver transplantation; NR; no response; OR; objective response; RECIST; Response Evaluation Criteria in Solid Tumors; TTP; time to progression; TTR; time to response;
Prospective Evaluation of Patients with Early-/Intermediate-stage Hepatocellular Carcinoma with Disease Progression Following Arterial Locoregional Therapy: Candidacy for Systemic Treatment or Clinical Trials
Keywords: زمان به پیشرفت; BCLC; Barcelona Clinic Liver Cancer; EASL; European Association for the Study of the Liver; HCC; hepatocellular carcinoma; LRT; locoregional therapy; NCT; National Clinical Trials; PD; progressive disease; TTP; time to progression; UNOS; United Network fo
Treatment of Hepatocellular Carcinoma Combining Sorafenib and Transarterial Locoregional Therapy: State of the Science
Keywords: زمان به پیشرفت; AASLD; American Association for the Study of Liver Diseases; AE; adverse event; BCLC; Barcelona Clinic Liver Cancer; CI; confidence interval; CR; complete response; DCR; disease control rate; DEB; doxorubicin-eluting bead; ECOG; Eastern Cooperative Oncolo
Research ArticlePhase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma
Keywords: زمان به پیشرفت; TACE; transarterial chemoembolization; HCC; hepatocellular carcinoma; TTP; time to progression; BCLC; Barcelona Clinic Liver Cancer; VEGF; vascular endothelial growth factor; RECIST; Response Evaluation Criteria in Solid Tumors; CTCAE; Common Terminology
RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: A meta-analysis
Keywords: زمان به پیشرفت; RRM1; Gemcitabine; NSCLC; Meta-analysis; Median survival; Time to progression
Research ArticleEfficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Keywords: زمان به پیشرفت; Hepatocellular carcinoma; Sorafenib; Subset analyses; Overall survival; Time to progression; Disease control rate;